Fundraising Fox

Biotech Late Stage Investors & VC Firms

652 firms in this list, with a median first check of $1M. 131 of them lead rounds. Generated from verified public data and updated continuously.

Andreessen Horowitz
Menlo ParkSeed–Late Stage$500K – $50M
134 people
New Enterprise Associates (NEA)
Menlo ParkSeed–Late Stage$200K – $40M
72 people
Bessemer Venture Partners
Redwood CitySeed–Late Stage$5M – $100M
61 people
Khosla Ventures
Menlo ParkPre-Seed–Late Stage$5K – $50M
51 people
Sequoia Capital
Menlo ParkPre-Seed–Late Stage$4.4M – $214M
47 people
F-Prime Capital
CambridgePre-Seed–Late Stage$3M – $10M
110 people
General Catalyst
San FranciscoPre-Seed–Late Stage$30M
38 people
OrbiMed
New YorkPre-Seed–Late Stage$1M – $75M
131 people
Kleiner Perkins
Menlo ParkPre-Seed–Late Stage$500K – $15M
50 people
GV (Google Ventures)
Mountain ViewSeed–Late Stage$250K – $50M
54 people
Norwest Venture Partners
Menlo ParkSeed–Late Stage$10M – $30M
35 people
RA Capital
BostonSeed–Late Stage
86 people
8VC
AustinPre-Seed–Late Stage$100K – $50M
58 people
DCVC (Data Collective)
Palo AltoPre-Seed–Late Stage$5M – $25M
44 people
Bain Capital Venture
BostonPre-Seed–Late Stage
162 people
Capria Ventures
BengaluruSeed–Late Stage$300K – $1M
27 people
Founders Fund
San FranciscoSeed–Late Stage$500K – $5M
38 people
Sofinnova Partners
ParisPre-Seed–Late Stage$540K – $27M
89 people
Venrock
Palo AltoSeed–Late Stage$500K – $10M
57 people
Octopus Ventures
LondonPre-Seed–Late Stage$130K – $1.3M
63 people
Gobi Partners
Hong KongPre-Seed–Late Stage$709K – $37M
74 people
Andera Partners
ParisPre-Seed–Late Stage
46 people
Alumni Ventures
ManchesterPre-Seed–Late Stage$100K – $10M
30 people
Frazier Life Sciences
Palo AltoSeed–Late Stage
77 people

Frequently asked questions

Who are the top biotech late stage investors & vc firms?
Top biotech late stage investors & vc firms include Andreessen Horowitz, New Enterprise Associates (NEA), Bessemer Venture Partners, Khosla Ventures, Sequoia Capital, F-Prime Capital, General Catalyst, OrbiMed — 652 firms in total meet the criteria.
What is the typical first check among biotech late stage investors & vc firms?
The median first check among the 652 biotech late stage investors & vc firms tracked here is $1M.
How many biotech late stage investors & vc firms lead rounds?
131 of the 652 biotech late stage investors & vc firms tracked here lead investment rounds.

Related lists

Data sourced from public filings and firms' own websites — see our methodology.